|
Howard A. (Skip) Burris III M.D. is chief medical officer and director of drug development at The Sarah Cannon Research Institute in Nashville where he is also an associate with Tennessee Oncology PLLC. Dr. Burris' research interests focus on developing investigational agents and evaluating these compounds in Phase I and II clinical trials. He has published papers on taxanes and topoisomerase I inhibitors. He currently serves on the American Society of Clinical Oncology (ASCO) Board of Directors and is a member of ASCO's Ethics Committee. He received his medical degree from the University of South Alabama and completed his residency and fellowship in hematology/oncology at Brooke Army Medical Center in San Antonio. While there he served as director of clinical research at the Institute for Drug Development of The Cancer Therapy and Research Center and was an associate professor at The University of Texas Health Science Center.
| 